Market Updates
Anglo American Lifts Production Outlook, Euronext to Buy Oslo Exchange
Sarla Buch
19 Feb, 2019
London
-
Anglo American lifted fiscal 2019 production forecast in Brazil after winning the regulatory approval for production expansion. Euronext intends to acquire Oslo stock exchange. Playtech declined after new Italian tax on gambling may reduce its fiscal operating profit.
In London trading, FTSE 100 index fell 19.66 or 0.3% to 6,746.28 and in Frankfurt the DAX index slumped 146.66 or 1.4% to 10,619.55.
In Paris, CAC 40 index declined 76.32 or 1.6% to 4,701.13.
Bourbon Corporation SA declined 4.3% to €4.05 after France-based shipping services provider looking for new financial partners to ensure its development and implement of strategic plan still under way and being consider the parameters of new financings are not yet determined.
Consus Real Estate AG slipped 1.3% to €7.58 after Germany-based commercial and residential property developer said revenues in the nine-month period ending in September surged from a year ago to €349.2 million.
Net in the period swung to profit €3 million from a loss of €4.1 million in a year ago period.
Capgemini SE slumped 3.3% to €88.14 after France-based professional consulting services provider announces that the as of December 1 its number of shares dropped 0.7% or 1,190,012 shares to 167,293,730 shares from January 1, 2018 at 168,483,742 shares.
Greencore Group Plc soared 7.6% to 178.55 pence after the U.K.-based sandwich maker said its plans to share buyback of up to £509 million and return to shareholders by way of a tender offer at the price of 195 pence per share, representing a premium of 17.5% to the closing price of December 19 as the share buybacks program during the year is completed.
Indivior Plc jumped 3.4% to 114.70 pence after the U.K.-based prescription drugs maker said that will launch cheaper version of popular opioid addiction treatment drug but sales of Sublocade have been slower than expected and also facing severe competition from generic rivals.
The drug maker reaffirmed fiscal 2018 revenues forecast between $990 million and $1.02 billion and net income in the range of $230 million to $255 million.
Annual Returns
Company | Ticker | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
---|
Earnings
Company | Ticker | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
---|